14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $225.62 $260.34 Thursday, 2nd May 2024 UTHR stock ended at $258.13. This is 1.17% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.47% from a day low at $254.06 to a day high of $260.34.
90 days $208.62 $260.34
52 weeks $204.44 $261.48

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Sep 27, 2023 $229.94 $234.26 $229.44 $232.47 253 089
Sep 26, 2023 $224.86 $230.02 $223.68 $229.91 283 261
Sep 25, 2023 $222.14 $225.36 $220.63 $224.06 297 383
Sep 22, 2023 $223.72 $225.00 $221.82 $222.75 161 004
Sep 20, 2023 $222.49 $226.58 $220.97 $223.93 285 400
Sep 19, 2023 $217.32 $221.52 $216.64 $220.67 222 456
Sep 18, 2023 $221.00 $221.58 $217.11 $217.48 298 011
Sep 15, 2023 $218.85 $221.07 $218.85 $220.24 568 340
Sep 14, 2023 $223.51 $224.09 $218.78 $219.49 234 894
Sep 13, 2023 $223.27 $224.64 $220.77 $222.34 258 174
Sep 12, 2023 $226.95 $226.95 $222.64 $223.78 149 100
Sep 11, 2023 $224.98 $225.94 $223.62 $225.32 163 369
Sep 08, 2023 $223.15 $225.45 $221.81 $225.13 155 912
Sep 07, 2023 $223.41 $224.26 $221.76 $222.63 256 039
Sep 06, 2023 $226.17 $226.17 $222.02 $223.36 183 521
Sep 05, 2023 $227.13 $227.13 $224.02 $225.23 230 807
Sep 01, 2023 $226.12 $229.49 $225.74 $228.05 248 819
Aug 31, 2023 $228.26 $230.59 $224.22 $224.36 267 082
Aug 30, 2023 $230.01 $231.14 $227.80 $228.44 115 522
Aug 29, 2023 $226.48 $229.98 $224.57 $229.53 174 563
Aug 28, 2023 $230.15 $230.36 $225.34 $226.01 188 670
Aug 25, 2023 $230.61 $230.61 $227.90 $229.01 189 081
Aug 24, 2023 $231.08 $233.75 $229.88 $230.53 142 965
Aug 23, 2023 $232.98 $235.19 $230.97 $231.46 249 732
Aug 22, 2023 $230.55 $233.93 $230.00 $231.06 172 553
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT